Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer

Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Advanced Hormone Sensitive Prostate Cancer

Sex eligibility

Male

Study type

Observational

Primary location

Groene Hart Ziekenhuis (there may be other sites in this country)

Gouda, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer

Exclusion criteria

Patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded
Planned intermittent or short-term (< 12 months) degarelix treatment
Planned addition of, or switch to another form of androgen deprivation therapy during the study

Treatment and study plan

degarelix

Drug

Other names: Firmagon®

Primary outcomes

Cardiovascular event rate in hormone naïve prostate cancer patients with cardiovascular comorbidity at baseline, treated with degarelix in daily practice

Time frame: Up to 1 year

Sponsors and collaborators

Lead sponsor

Ferring Pharmaceuticals

Industry

Registry information

Important dates

Study start: 2014
Primary completion: 2017
Study completion: 2017
First posted: Sep 1, 2014
Registry last updated: Nov 27, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.